Sanofi-Aventis S.A. (SNY)
$43.41 0.00 (0.00%)
17:16 EST SNY Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 107.59B
PE Ratio 29.04
Volume (Avg. Vol.)
Day's Range 43.41 - 43.41
52-Week Range -
Dividend & Yield 1.86 (4.29%)
SNY Stock Predictions, Articles, and Sanofi-Aventis S.A. News
- From InvestorPlace
- From the Web
Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives. With them, we can solve Covid-19.
GlaxoSmithKline and Sanofi stock are rallying in early trading on Friday thanks to news they would supply the EU 300 million vaccine doses.
Even a vaccine that's 50% effective with some side effects would be a game changer. The Trump Administration is throwing billions into that hope and investors are seeing big profits.
SNY stock is no longer a sleepy passive investment. Under a new CEO, Sanofi is less reliant on diabetes and heart drugs and looking to buy pre-market cancer blockbusters.
Biotech stocks are on fire at the moment. That said, here are five names from the sector that offer long-term value and strong fundamentals.
As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
Biotech stocks offer more than just capital gains; some of them pay dividends. Here are three dividend-paying biotechs to consider.
Biotech stocks can still pay you some big yields. Here are five of the best dividend stocks in the pharma sector.
SNY stock beat on earnings and missed on revenue, but sales of newer drugs as well as a low P/E and a high dividend show promise for Sanofi.
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
Sanofi (SNY) stock was down Friday after the company released disappointing sales for its first-quarter 2018 earnings report.
Sanofi (SNY) inks second multi-dollar deal this month. Since the earlier deal last Monday, SNY stock gained 2.6% in a week.
Volatility has send MannKind stock's options prices through the roof. You could sell option premium here, but is MNDK worth the risk?
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being.
Sanofi SA (NYSE:SNY) is a constituent of the 134 company Pharmaceuticals GICS industry group, which is a segment of the 782 company GICS Health Care sector. SNY's market value is $112.1 billion which places it in the top 10% of its industry group. Portfolio Grader's current ranking for SNY puts it 53 among the 134 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 307 among the 782 companies in the sector, and number 1,707 in the nearly 5,000 company Portfolio Grader universe.
From Talk Markets
Navellier RatingsPowered by Portfolio Grader